Oliver Rittgen
CFO
Replay available
Clariant (SIX Swiss: CLN) reported Q3 2026 results on this call. Replay available.

On 6ix: 6ix.com/event/clariant-ag-0qjsl-q3-2026-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Ladies and gentlemen, good afternoon. My name is Andreas Schwarzwaelder, and it's my pleasure to welcome you to this Q3 conference call. Joining me today are Conrad Keijzer, Clarion CEO, and Oliver Rittgen, Clarion CFO. Conrad will start the call by providing a summary of the third quarter developments, followed by Oliver, who will guide us through the business unit results. Conrad will then conclude with the outlook for the full year 2026. There will be a Q&A session following our presentation. At this time, all participants are in listen-only mode. I would like to remind all participants that the presentation includes forward-looking statements that are subject to risks and uncertainties. Listeners and readers are therefore encouraged to refer to the disclaimer on slide 2 of today's presentation.
0:48 As a reminder, this conference call is being recorded. A replay and transcript of the call will be available in the investor relations section of the Clarion website. Let me now hand over to Conrad to begin the presentation.
1:01 Thank you, Andreas. In the third quarter of 2026, Clarion delivered strong sales growth in local currency. We delivered sales of 968 million Swiss francs, representing an increase of 5.6% in local currency. Excluding portfolio pruning, sales increased by 6.7% in local currency. Strong growths in care chemicals and adsorbents and additives reflected positive pricing and volumes, while catalyst volumes remained impacted by the Middle East conflict. Our EBITDA margin before exceptional items decreased by 230 basis points year-on-year to 15.6%.
1:51 The improvement in adsorbents and additives was more than offset by the normalization of corporate costs following a prior year one-off benefit and the impact of a less favorable mix and raw material related effects. We increased our free cash flow conversion rate by 9 percentage points on a last 12-month basis to 48% from 39% in the prior year period due to improved operating cash flow, disciplined capital spending and effective networking capital management. Our guidance for the full year 2026 remains unchanged. With continued volatility and uncertainty related to the Middle East conflict.
2:41 For the final quarter, we have a strong order book, particularly in catalysts, and expect continued strong business momentum in care chemicals and additives. Margins in the fourth quarter will be driven by top-line growth and a positive business mix. This will be supported by our performance improvement programs and continued active cost and pricing management. Now moving to further detail on our sales performance in the third quarter. Pricing increased by 5.7% and was positive across all three business units. Driven by strong value-based pricing actions to largely offset significant inflationary raw material prices.
3:34 Volumes decreased by 0.1%, impacted by the Middle East conflict and our portfolio pruning measures. Excluding portfolio pruning, group volumes grew by 1%. Volumes grew by 2.1% underlying in chemicals and by 1% in absorbents and additives, while catalyst volumes declined by 1.9%. The reported revenue figure benefited from a 1.3% currency tailwind. Turn into profitability. EBITDA before exceptional items decreased by 6.5% year-on-year to 151.5 million Swiss francs.
4:24 This corresponds to a margin of 15.6% compared to 17.9% in the prior year. Let me provide some more details on the margin development. The 230 basis point decline reflects two effects of broadly similar magnitude. First, a one-off year-on-year impact of roughly 100 basis points from the phasing of provisions in corporate costs. Second, a roughly 100 basis points effect of volatile raw materials on cost and valuation of inventory in chemicals and catalysts. Our performance improvement programs supported margins across the group, particularly in adsorbents and additives.
5:16 Pricing largely offset 12% higher raw material, 9% increase in energy, and 24% higher logistics costs across the group in the third quarter versus prior year. Looking at our savings programs in more detail. Our performance improvement programs target total run rate savings of 100 million Swiss francs by 2027. We continue to expect 90 million Swiss francs run rate savings by the end of 2026. In the third quarter, we achieved savings of 10 million Swiss francs, which brings the cumulative run rate savings achieved to 79 million Swiss francs.
6:05 The implementation of the programs resulted in restructuring charges of 6 million Swiss francs in the third quarter, bringing total program restructuring charges to 99 million Swiss francs. Key measures announced in the third quarter include an additional headcount reduction of around 70 positions, increasing the total announced reduction to around 700 positions. We continue to implement targeted cost management initiatives globally across the business units and corporate functions. With that, I now hand over to Oliver for further details on our business performance in the third quarter.
6:54 Thank you, Conrad, and good afternoon, everyone. Let us now look at the third quarter development by business unit. In Care Chemicals, we recorded strong underlying growth driven by the industrial businesses and personal and home care. Sales increased by 8.7% in local currency when excluding our portfolio pruning measures and by 6.6% when including them. Pricing was up 6.5%, reflecting increased formula-based prices, and the continued implementation of value-based pricing in response to clearly inflationary input costs. Volumes increased by 0.1%, including the impact of portfolio pruning, while underlying volumes grew by 2.1%. Sales and stress ranks increased by 8.4%, reflecting a 1.8% currency tailwind.
7:56 Growth was driven by industrial applications, base chemicals, mining solutions, and personal home care, supported by positive pricing and strong volume growth. Sales and crop solutions were flat with slightly lower volumes. Here, we expect a volume recovery in Q4. Sales and oil services declined due to the portfolio pruning effect behind our exit in Argentina, and the impact of the Middle East conflict. We saw an underlying decline at a low single-digit rate over a particularly strong previous year quarter. We recorded an EBITDA before exceptional items of 93 million Swiss francs, representing a 0.3% decrease compared to the prior year.
8:49 This translated into an EBITDA margin before exceptional items of 17.5%, A 150 basis points decline, reflecting business mix, as we saw an overproportional contribution from industrial businesses, and the effects of volatile raw materials on costs and valuation of inventory. In catalysts, sales increased by 1.8% in local currency and by 1.3% in Swiss francs. While pricing was up 3.7%, volumes declined by 1.9% versus the prior year period due to the significant impact of the conflict in the Middle East, with high margin orders being delayed.
9:38 Sales in propylene more than doubled against a very low comparison base, while sales in specialties were flat. Sales in ethylene decreased at a double-digit percentage rate, especially being affected by the shifts of orders. Syngas in fuels decreased at a low single-digit rate, with good growth in fuel sales behind the investments in data centers, offset by softer demand in syngas. EBITDA before exceptional items decreased by 29.4% to 23.1 million Swiss francs, representing a corresponding margin of 13.3% compared to 19.1% in the prior year. Half of that decline was driven by volume impact from the conflict in the Middle East, resulting in lower operating leverage, along with a less favorable business mix.
10:35 The other half results from a negative inventory valuation effect with lower precious metal prices. Continued delays and orders in the Middle East and other regions remain a factor, as there is still a significant number of forced majeures and shutdowns in the industry. However, we are seeing a normalization in Asia and a reduced number regarding our direct customers. This results in a solid order book and favorable business mix, providing confidence for our expectation to deliver a strong final quarter of the year. Moving to absorbance and additives.
11:20 We recorded continued strong top-line growth driven by additives. Sales increased by 6.4% in local currency and by 7.9% in Swiss francs, with pricing up In the adsorbent segment, sales increased modestly as growth in renewable fuel applications in the United States more than offset lower demand in industrial segments and editable oil purification in EMEA and APEC. In additives, sales increased at a double-digit percentage rate driven by strong price and volume growth. For polymer solutions, we saw continued strong demand, particularly in flame retardants and waxes, while coatings and adhesives benefited from significant growth in passive fire protection.
12:17 EBITDA before exceptional items increased by 15.1% to 48.9 million Swiss francs, while the corresponding margin increased to 18.5% versus 17.4% in the prior year. The 110 basis points improvement reflected positive mix effects, active margin management, and contributions from our performance improvement programs. And with this, I close my remarks and head back to Conrad. Thank you, Oliver.
12:52 Let me conclude with our guidance for 2026. For the full year, we continue to expect a challenging and volatile market environment with continued geopolitical uncertainties and risks. Oxford Economics Forecast now assumes global GDP growth of 2.6%, broadly in line with their 2.5% in July. While expected global chemical industry growth has decreased to negative 0.6%, from 1% in July, driven by a prolonged Middle East conflict and related elevated energy price levels. Declines are expected in the Middle East and Africa, minus 5.2%, the US, minus 1.5%, and in Europe, minus 0.2%, while growth in the chemical industry in China slows down to 1.4% in 2026.
13:54 The ongoing conflict in the Middle East continues to negatively impact orders in catalyst and Middle East oil services and puts inflationary pressure on raw material, energy and logistics costs. To mitigate these effects, we continue to deliver our proven value-based pricing, supported by active cost measures. Our guidance for 2026 remains unchanged, with sales expected to be around 2025 levels in local currency and an EBITDA margin of around 18% before exceptional items. This outlook is supported by the continued strong business momentum in chemicals and additives and a stronger order book for the final quarter of 2026, particularly in catalysts.
14:50 We expect a quarter in Catalyst in line with prior year and higher margins on a positive business mix. We expect to achieve free cash flow conversion of over 45% in 2026. With that, I turn the call back over to Andreas.
15:10 Thank you, Conrad and Oliver. Ladies and gentlemen, we are now opening the floor for questions. To ensure everybody has a chance to participate, please ask no more than two questions per person. Thank you for your cooperation. Sandra, please go ahead. Thank you, Andreas. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on the telephone. You will hear a tone to confirm that you've entered the queue. If you wish to remove yourself from the question queue, you may press star and two. Questions on the phone are requested to disable the loudspeaker mode and eventually turn off the volume of the webcast while asking a question. Anyone with a question, may press star and one at this time. Our first question comes from Christian Veit from Kepler-Chevreux.
15:57 Please go ahead.
16:00 Yes, thank you and good morning, good afternoon actually and congrats on the Quite good results in a challenging time. Two questions, please. First of all, your full-year guidance. What does support the rather sharp improvement in Q4 that is required to reach the 18% full-year EBITDA margin? My calculations suggest something like 21% EBITDA margins in Q4 would be required to get to that. And then the second question on the catalyst side, I appreciate your comments on the demand revival in Asia but how does the Middle East look and do you see any sign of hope that operations in the Middle East slash Middle East conflict are stabilizing?
16:53 What do we hear on the ground? Thanks very much.
16:57 Thank you, Christian. The two questions are a bit related because what makes us feel confident about the guide is actually Q4 and how it comes in. So we've seen in October actually a good start of the quarter in all business units. All business units are actually up in revenue compared to prior year. We particularly see a very strong order book in Catalyst, and not only in terms of revenue, which we think will end in line with prior year, which was quite strong, but also in terms of mix. It should actually be a more favorable mix than prior year. Maybe specifically on Catalyst to your question, what we see in Catalyst in the Middle East is Thank you very much.
18:12 and many more. Thank you very much. Very helpful, Conrad. Thank you. The next question comes from Thea Badaro from BNP Paribas. Please go ahead.
18:59 Yes, hey, good afternoon. Two questions, if I may. The first one is on care chemicals. Can you give us a bit more color on why the margins were so weak in the quarter apart from the inventory revaluation? And the second one is on maybe a slightly sensitive one on the litigations. Could you please provide us with a bit more color on what would it take you to settle the case Is this a potential scenario you could consider at some point? Thank you.
19:32 Yeah, so on the claims, we can be very short. There is no news on the claims. So as expected, Shell and the Stichting Foundation filed for an appeal. And we continue to be very pleased with the clear decision from the Amsterdam District Court in July, who confirmed our view. With regards to chemicals, and I'll let Oliver provide a bit more detail, but you did see actually a very strong Q2 with 300 basis points up in and many others. Thank you very much.
20:39 Thank you. Maybe to just add to the second component of the margin performance in care chemical, Conrad talked about the quarter over quarter and the inventory effect already. The second component is the mix that we saw in care chemicals in the third quarter. When you look at the segments, we had a very strong growth and over-proportionate growth, I would say, in the industrial segments. So industrial applications, the base chemicals, and in that sense, it's a bit of a margin question on that side. We also had growth in personal and home care and mining, but as I said, the industrial part of that was over-proportional and hence came with different margins and that in combination with the inventory led to the slightly lower margin versus previous years.
21:39 The next question comes from James Hooper from Bernstein. Please go ahead.
21:44 Hi, good afternoon. Thank you for taking my questions. The first is around the medium term guide. So congratulations on achieving the free cash flow guide. But can you firstly help me bridge how you're expecting to get to the local currency revenue guide and then next year's EBITDA margin? Particularly in the local currency revenue guy, it looks like you'd need to do a considerable deal to get there. And the press have been linking you to Ashton, for example. And then second question, Carmel, I just want to pick up on your remarks that you made on TV this morning about unfair competition from not just China, but also the U.S., Can you give us a little bit of context about any measures that you see implemented by Europe and whether they'll be kind of just anti-dumping or in the context of the quotas, please? Thank you.
22:43 Yeah, James, I'll let Oliver comment a bit more specifically on medium-term guide and free cash flow. In terms of the competition, I can mention that what was asked this morning was China competition in Europe and what the view is of the chemical industry on that. We actually just had our board meeting for CEFIC the other week in Portugal where we came together. with all of the representatives from the industry. And by and large, the view is that global trade has always been a positive for Europe. Historically, 35% of production in chemicals in Europe was exported. So export has been a growth driver for the chemical industry in Europe. What is obviously not good is unfair competition.
23:28 And the point of view in the industry and SAFIC point of view is Thank you very much. What is less balanced is the trade with the U.S., where we still have about a 12.5% tariff for our products getting into the U.S., and there's no tariff for products from the U.S. going into Europe. And with the increasing difference in energy costs, the gas price is now actually a factor 10 or 12 more expensive in Europe than in the U.S. This is becoming an issue, and there's quite a lot of import of polymers now into Europe.
24:32 Yeah, what for Clarion is still an important comment to make is we have 68 factories globally. So tariffs for us are not a significant impact on our results. We produce by and large in a region for a region.
24:50 all over to you on the medium term. Hello, James. On the medium term, I mean, first of all, I share your view on the cash performance. We are also pleased with the above 45% that we are guiding for this year. The medium term guide on cash performance was 40%. So the cash program that we have launched last year is really taking traction, the discipline on working capital, the discipline on Thank you very much. but that is predicated on the market being somewhere in the range of 2-4% and then on margin we said 19-21% with the round 18 that we will finish this year depending on the market outlook that we take for next year that is how we look at that medium term range still but it's a bit early to talk now already about guidance for next year on that one we're going to come back in February.
26:15 Sorry, just to follow up. Just on the M&A question as well, is there a route to making that medium-term guidance?
26:29 I mean, on the M&A, there's nothing to add to what we always say on M&A. We're going to stay disciplined on any M&A execution. We're looking at the opportunities when they pose them to us. We're committed to our investment grade rating. And yeah, that's pretty much what we can say on M&A strategy. Thank you very much. Thank you, James. The next question comes from Julia Winkelmann from Bank of America. Please go ahead.
27:10 Hi, thanks for taking my questions. So the first one would be on the capitalist business. Did I understand correctly? You said sales are similar to last year and then the mix is better. So it should either, that should be up year on year. I think last year was around 60 million or so. Can you maybe give a bit more color on what contracts are driving this sequential improvement? Is it one big order? Is it multiple orders? And which product is it in? Which region? And are these deliveries scheduled for towards the beginning of the quarter or more towards the end? So in other words, is there any risks for delays into 2027?
27:59 And then my second question would be on CAPEX. I think you said you expect it now in the lower end of the range, but historically it has been more above 200 million. Is there any specific projects or areas where you have decided to reduce CAPEX? And if so, why? And is that also the run rate we can expect for 2027 and beyond? Then the last question would be on your, I guess, a follow-up question on M&A. I think you previously indicated that your preference would be bolt-on acquisitions and probably more the consumer and market space. What target size would you consider a bolt-on and is it still the priority or would you also consider larger ones? Thank you.
28:55 Thanks for your questions. We'll try to take all three. I think Oliver can comment on CapEx. Just to repeat what Oliver just said on M&A, let's be clear. Our strategy in the company is first and foremost about organic growth and margin improvement. and then we actually have bold on acquisitions on top so we would only do acquisitions if and when they strengthen our core segments and we will be disciplined we have a quality ambition not a size ambition and Oliver mentioned for us very important also to maintain Thank you very much. Thank you very much.
30:12 Julia, on the CAPEX.
30:38 We indicated the range of 150 to 175 million and also that we would likely finish this year at the lower end of that range. I mentioned that we have a very good discipline now on how we look at capex and the spending. and that's also something that of course we will continue going forward. That level of 150 million roundabouts is not an unusual level, that was also the level that we saw last year and you're right, in the period of 2020 to 2024 we were on higher capex rates But those were the heavy investments that we also did, like in China, in Daya Bay, to build up additional capacity and to further strengthen the strategy that Conrad was also mentioning, that we produce and source region for region. And that was part of that strategy to significantly expand our China presence, for instance.
31:46 But that capacity is now built. We feel that we have sufficient capacity for the growth ambition that we have, and hence that level of 150 to 175 million is more of a normalized capex level for us. Thank you.
32:06 Thank you, Julia. The next question comes from Chetan Udeshi from JP Morgan. Please go ahead.
32:16 Hi, thanks for taking my questions. I was just trying to reconcile your comments on strong Q4 order book with what you've reported. It's quite unusual for a company to miss and say Q4 is actually looking great after missing Q3. And when I look at your volumes in care chemicals, flat, your volumes in additives is up like maybe 1%. It doesn't seem like there is a sort of, you know, broad-based strength in demand as you seem to be just suggesting. So I was saying you actually seen an acceleration of trends in Q4 and hence you think Q4 will be better. I'm a bit confused in the comments on Q4 versus what you actually have reported for Q3.
33:05 And the second question, I mean, apologies again to come to this M&A topic because I remember I asked this question to you, Conrad, last conference call around The need for industry consolidation and the role Clarion will play. And I think if I'm not completely mistaken, you said at that point the focus is on bolt-on attribution. And since then, we've seen the news flow of Clarion actually looking to buy Ashland with a private equity. It's not entirely clear how should we read what your intentions are and how are you even looking to fund an acquisition of that size if there is one in the pipe. Thank you very much.
33:54 First on the strong fourth quarter, I think you mentioned flat volumes in care chemicals. I think it's important to realize that if you're correct for pruning, we're actually running a 2% volume year on year in care chemicals in additives. You mentioned 1%. That's actually the combined growth between additives and absorbents. And what we're seeing, particularly in absorbents, is a pickup in business, especially in the US, because of the new renewable fuel incentives. Additives already is running well above a 1% CAGR. And we actually see pockets there, particularly our flame retardants, where we're running a double-digit growth.
34:40 So where we see volume headwinds in the business is actually in catalyst, the minus 2%, which is entirely related to the Middle East. And what we're also seeing in the Middle East is that actually In the Middle East itself, there still are quite a number of force majeures, but outside the Middle East, we see that actually easing. So this is all confirmed in our order book. Q4 is always seasonally strong for Catalyst. That's how the business works. People sort of run out their, complete their CapEx budgets for the end of the year. Many times it's part of CapEx. There has been always this seasonality. So I think we are actually relatively optimistic.
35:29 We see growth back in the business, not just because of pricing. No, we see underlying 2% growth in chemicals. We see more than 1% growth in additives and absorbents. On the consolidation question that you had, or you were more or less asking me to speculate on rumors, you know it's a good tradition in our industry that we don't comment on specific rumors or cases. But I will repeat that for us it is important that we make acquisitions. and more segments in our company. And to your question on funding, the investment grade for us is absolutely an important priority. So whatever we do has to stay within those parameters.
36:26 Got it, thank you.
36:28 Thank you, Chetan. The next question comes from JD Pandaria from Onfield Research. Please go ahead.
36:37 Thank you. First question is, again, sorry to ask, but on catalyst, if you look out the next sort of 12 months to 18 months, very curious to understand the cataphene cycle and if you have any other New products in the pipeline in terms of Catofein's refill demand as well as, I guess, new plants, if there are any. So I just want to understand how would the mix evolve given Catofein was such a key driver of your mix in the previous peak, basically. The second question is around, actually, it's the same question but for two businesses. you know if you zoom into your personal and home care where you did the Lucas Meyer acquisition and then if you look at the flame retardants business where you added capacity in China I understand both these businesses are higher margin businesses and they've been doing at least from the outside in quite well but the reported margin for the divisions hasn't really progressed much So can you just give us some color, how are these businesses doing margin-wise?
37:48 And if they're doing well, then what is the offsetting factor where margins have gone down and therefore the true color is not reflected? And the last question sort of ties into what Chetan was asking, really. If you look at Clarion's portfolio today, I mean, what areas, it seems that you want to put more money in care chemicals. So to be counter, then what is the strategic relevance of absorbance and additives? Like, why would you not look at the strategic review for that, you know, if you're getting a good valuation to potentially fund your plants in care chemicals, if that is the case? Thank you.
38:33 Thank you, Jadid. The last one I can be short about. If we would do strategic reviews, we would do them internally and not necessarily on these calls. In terms of the M&A, I have not so much to add beyond prior comments. With regards to Catalyst, I'll make a few comments, and I think Oliver can comment on the margin progression, but it's fair to say that Thank you very much. and we've been hit with force majeures within the Middle East but also outside the Middle East. I think what you will see is even in a continued turmoil scenario in the Middle East, you'll see a recovery of those plants that are on force majeure I think there's a second effect that we haven't talked about often but that is that actually volumes that are out of the market from the Middle East are actually partly absorbed in the US and in Europe and here you see higher operating rates Thank you very much.
40:32 based on the current turmoil but we are seeing increased business for refill outside the Middle East and I think that should be reflected in a recovery scenario for next year. Finally on new builds what is encouraging is that we see projects coming in for the longer term. We've just been awarded what is actually the biggest Catofin project so far, a 1.2 million tons Catofin line in China. Zhejiang Petrochemicals has actually given us that order for new build already. That will be more towards the end of 27 or 28 in terms of when we record that sales. but you are seeing actually a wave of new builds ahead of the 2030 peak carbon year in China that is coming in and that's actually very encouraging.
41:33 Oliver, if you can comment about the margin project progression.
41:37 Yeah, sure. Hello, Jadid. I mean, it's essentially a question that you're raising on overall care chemicals and additive absorbance margin developments. Let me start with care chemicals and... We alluded to this already a little bit. On the personal home care side, we are very pleased with the margins, both from the Lukas Meyer side and the acquisition, but also from our other businesses in the segment. Margin development positive for the quarter overall and also for the nine months that we look into. And The third quarter is particularly impacted by the mix, as we said, right?
42:28 The industrial businesses, they are overproportional in the sales contribution and with that also from the margin contribution versus the more consumer-related businesses like personal home care and crop solutions. Thank you very much. If you look at the nine months for care chemicals, margins are up by 30 basis points. So that shows you the direction also how we look at it from a full year basis.
43:13 And then for additive and absorbance, here you're right, additives is performing really well on the growth side, both volume and price. Thank you very much. And with that continuous strong momentum that we see in additives and also in parts of the absorbance businesses, we are also positive for the Q4 to land a margin above the prior year, both for care and for additives and absorbance.
44:02 If I may squeeze one follow-up on Catalyst in the Middle East. Conrad, if you could give us some color, what is the product portfolio? Is it very petrochemical heavy in the Middle East? And is the margin profile of Clarion's Middle East Catalyst higher than the average of Catalysts?
44:22 Yeah, well, what we have in the Middle East is roughly 15% of our revenue in catalysts sits in the Middle East. So it's a very sizable piece of the business. It is heavily skewed towards petrochemicals as well as syngas. So it's basically catephine and syngas. And these are, as you would expect, the higher margin products. The last question for today comes from Lisa Deneve from Morgan Stanley. Please, go ahead. Hi, thank you for my questions. I have a number of follow-ups.
45:09 In the previous question, you made a comment around your crop solution segment and your expectation for better volumes in the fourth quarter. I mean, can you give a little bit more shed light what you're seeing in the underlying market in terms of the fourth quarter, but maybe also into 2027 and how you're seeing the competitive landscape on your customer side? Any thoughts on that would be great. So that's for crop protection. Secondly, on the ANA segment, I mean, you're seeing better U.S. absorbance demand. You're seeing strong demand for flame retardants. How should we think about the ANA margins in the fourth quarter? I mean, should we just assume they're significantly up year and year, or should we actually model them closer to the third quarter? So any thoughts on that would be great as well.
45:57 And then finally, The follow-up on the Ethylene Price Cartel investigation, litigation, sorry. Concerning the appeal of Shell and the Stichting Foundation, I mean, can you share how an appeal process like that will work? I mean, should we see this as a simple retrial of the previous submitted case or will completely different arguments be brought to the table here? Any thoughts on that would be great as well. Thank you.
46:25 Yeah, okay, Lisa. So, starting with the last one, and then I will make some comments on crop, and then I think Oliver can talk a bit about the margin progression in ANA. Yeah, on litigation, how this would basically look like, this appeal, is that there will be hearings first. These will be procedural hearings somewhere into next year. But I think what's important is actually to look at the The Netherlands in July, which was actually an overwhelmingly positive outcome for Clarion and and many others that we as Clarion met earlier on about this case.
47:14 As far as crop solutions and what we expect volume-wise and what we see I think also relative to our competitors, I think Oliver already commented on it with an overall flat performance in Q3, which was slightly negative on volume and positive on price. We are seeing increased volumes in Q4. That is more also actually competitor dynamics where we are thinking that we are gaining some business and even our Q3 result, which was flat. If you compare that with some of what our competitors have announced so far, The flat overall performance versus prior year is actually not a bad performance at all in crop as we speak. Oliver, maybe you can also share some of the comments on margin progression for ANA in Q4.
48:07 Lisa, that was a bit what I mentioned to Jadeep. I mean, for Q4, when you take it together, we are expecting a continuous strong momentum in the additive business, both in Thank you very much.
48:53 Thank you very much.
Follow Clariant AG into a list and get an email when it puts out news.
CFO
Analyst, JPMorgan
Investor Relations
CEO
Analyst, Bernstein
Analyst, Kepler Cheuvreux
Analyst, Bank of America
Analyst, Morgan Stanley
Analyst, BNP Paribas
Analyst, Onfield Research